Predictors of Global Non-Motor Symptoms Burden Progression in Parkinson’s Disease. Results from the COPPADIS Cohort at 2-Year Follow-Up

• Published in: Journal of personalized medicine Vol. 11; no. 7; p. 626
• Main Authors: Santos-García, Diego, de Deus, Teresa, Cores, Carlos, Canfield, Hector, Paz González, Jose, Martínez Miró, Cristina, Valdés Aymerich, Lorena, Suárez, Ester, Jesús, Silvia, Aguilar, Miquel, Pastor, Pau, Planellas, Lluis, Cosgaya, Marina, García Caldentey, Juan, Caballol, Nuria, Legarda, Ines, Hernández-Vara, Jorge, Cabo, Iria, López Manzanares, Lydia, González Aramburu, Isabel, Ávila Rivera, Maria, Catalán, Maria, Nogueira, Victor, Puente, Victor, Dotor, Julio, Borrué, Carmen, Solano, Berta, Álvarez Sauco, Maria, Vela, Lydia, Escalante, Sonia, Cubo, Esther, Carrillo, Francisco, Martínez Castrillo, Juan, Sánchez Alonso, Pilar, Alonso, Gemma, López Ariztegui, Nuria, Gastón, Itziar, Kulisevsky, Jaime, Blázquez, Marta, Seijo, Manuel, Rúiz Martínez, Javier, Valero, Caridad, Kurtis, Monica, de Fábregues, Oriol, Ardura, Jessica, Alonso, Ruben, Ordás, Carlos, López Díaz, Luis, McAfee, Darrian, Martinez-Martin, Pablo, Mir, Pablo
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 30-06-2021; MDPI
• Subjects: Alzheimer's disease; Comorbidity; Dementia; Dopamine; Drug dosages; Movement disorders; Neurodegenerative diseases; Pain; Parkinson's disease; Patients; Precision medicine; Questionnaires; Regression analysis; Sleep; Sleep disorders; Variables; Spain
• ISSN: 2075-4426; 2075-4426
• DOI: 10.3390/jpm11070626

Background and Objective: Non-motor symptoms (NMS) progress in different ways between Parkinson’s disease (PD) patients. The aim of the present study was to (1) analyze the change in global NMS burden in a PD cohort after a 2-year follow-up, (2) to compare the changes with a control group, and (3) to identify predictors of global NMS burden progression in the PD group. Material and Methods: PD patients and controls, recruited from 35 centers of Spain from the COPPADIS cohort from January 2016 to November 2017, were followed-up with after 2 years. The Non-Motor Symptoms Scale (NMSS) was administered at baseline (V0) and at 24 months ± 1 month (V2). Linear regression models were used for determining predictive factors of global NMS burden progression (NMSS total score change from V0 to V2 as dependent variable). Results: After the 2-year follow-up, the mean NMS burden (NMSS total score) significantly increased in PD patients by 18.8% (from 45.08 ± 37.62 to 53.55 ± 42.28; p < 0.0001; N = 501; 60.2% males, mean age 62.59 ± 8.91) compared to no change observed in controls (from 14.74 ± 18.72 to 14.65 ± 21.82; p = 0.428; N = 122; 49.5% males, mean age 60.99 ± 8.32) (p < 0.0001). NMSS total score at baseline (β = −0.52), change from V0 to V2 in PDSS (Parkinson’s Disease Sleep Scale) (β = −0.34), and change from V0 to V2 in NPI (Neuropsychiatric Inventory) (β = 0.25) provided the highest contributions to the model (adjusted R-squared 0.41; Durbin-Watson test = 1.865). Conclusions: Global NMS burden demonstrates short-term progression in PD patients but not in controls and identifies worsening sleep problems and neuropsychiatric symptoms as significant independent predictors of this NMS progression.